Nicholas Wrigley

Investigators of a phase 2 study suggest that relacorilant may add to a ‘sparse’ field of effective treatment options for patients with platinum-resistant or refractory ovarian cancer.

Patients with low-grade serous ovarian cancer appear to have worse survival outcomes following treatment with neoadjuvant chemotherapy.

Prospective, real-world data indicate that most patients with colon or rectal cancer who undergo surgery remain independent.

Increasing radiation doses to the whole heart appear to correlate with higher risks of valvular disease, coronary artery disease, and heart failure in childhood cancer survivors.

Investigators of a prospective study of 1253 patients find that outcomes with the experimental homoharringtonine-based regimen either meet or exceed those with a classic etoposide-based regimen.

When combined with brain stereotactic radiosurgery, trastuzumab emtansine appears to produce minimal acute skin effects among patients with non-metastatic breast cancer.

Data indicate that replacement of vincristine with polatuzumab vedotin in combination with etoposide, prednisone, cyclophosphamide, doxorubicin, and rituximab should be further explored in large B-cell lymphoma.

Investigators of a cohort study report that the withdrawal rate from clinical trials in oncology appear to be higher among Hispanic patients and across placebo-controlled trials, but lower in trials with radiation use as part of therapy.

A larger, phase 2 trial is planned to further evaluate pembrolizumab plus doxorubicin, vinblastine, and dacarbazine in patients with newly diagnosed Hodgkin lymphoma.

Phase 2 data support administering trastuzumab in combination with ramucirumab and paclitaxel for patients with HER2-positive gastric or gastroesophageal junction cancer.

The experimental agent appears tolerable in patients with newly diagnosed FLT3-mutated acute myeloid leukemia in a phase 1b trial.

Findings from a retrospective analysis suggest an association between bridging therapy and poorer outcomes among patients with aggressive, relapsed/refractory B-cell non-Hodgkin lymphoma.

Data from the phase 2 FIRE-4.5 trial suggest that cetuximab further reinforces a bevacizumab-based chemotherapy regimen as the frontline treatment of choice for BRAF-mutant, metastatic colorectal cancer.

The safety profile of selpercatinib in patients with RET fusion–positive non–small cell lung cancer in the phase 3 LIBRETTO-431 study is comparable with previous reports.

The safety profile of upifitamab rilsodotin in the phase 1b/2 UPLIFT trial is consistent with prior reports of the agent in those with platinum-resistant ovarian cancer.

Combined with chemotherapy, blinatumomab appears tolerable and beneficial in a subgroup of pediatric patients with B-cell acute lymphoblastic leukemia in first relapse but does not yield better survival outcomes in the overall population.

Patients at high risk for breast cancer appear to have higher rates of nonadherence to screening guidelines vs those at average risk.

Among patients with low-grade, non–muscle invasive bladder cancer, intravesical UGN-102 appears to improve outcomes vs standard surgical treatment in two phase 3 trials.

Investigators of a retrospective study report that an AI deep learning model may also predict negative margin probabilities better than conventional modalities.

Investigators of a meta-analysis report no significant difference in outcomes when comparing trimodality therapy and radical cystectomy for the treatment of muscle-invasive bladder cancer.

The fourth-generation tyrosine kinase inhibitor yields several partial responses and a tolerable safety profile in a small population of patients with EGFR-mutated non–small cell lung cancer in a phase 1 trial.

The approval from the European Commission is based on findings from the phase 3 TROPiCS-02 study.

The potential reduction in relapse in patients with unresectable chronic lymphocytic leukemia appears to happen regardless of minimal residual disease status 3 months post-treatment and immunoglobulin heavy-chain variable region mutational status.

JZP458 is part of a multi-agent chemotherapy regimen for lymphoblastic lymphoma and acute lymphoblastic leukemia, and can be used for adult and pediatric patients.

Data from the phase 3 PRIME trial show improved survival outcomes with frontline niraparib maintenance therapy among patients with advanced ovarian cancer.

The European Commission will evaluate elacestrant in locally advanced or metastatic breast cancer after receiving a positive opinion on approval from the CHMP.

Thoracic radiotherapy appears to be tolerable and effective in a real-world cohort of patients with extensive-stage small-cell lung cancer.

Data from a phase 1b dose escalation and expansion study highlight an encouraging duration of remission using APVO436 plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Umbralisib in combination with ublituximab and venetoclax appears tolerable and yields responses in a small cohort of patients with mantle cell lymphoma.

Findings from a phase 2 study may inform the design of future trials assessing fecal microbiota transplants in patients with acute myeloid leukemia.